Heidi A Hanson1, Christopher Martin2, Brock O'Neil1, Claire L Leiser3, Erik N Mayer2, Ken R Smith3,4, William T Lowrance2. 1. Department of Surgery and Population Sciences, University of Utah, Salt Lake City, Utah. 2. Division of Urology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 3. Department of Population Sciences, University of Utah, Salt Lake City, Utah. 4. Department of Family and Consumer Studies, University of Utah, Salt Lake City, Utah.
Abstract
PURPOSE: There is a differential in prostate cancer mortality between black and white men. Advances in precision medicine have shifted the research focus toward underlying genetic differences. However, nonbiological factors may have a large role in these observed disparities. Therefore, we sought to measure the relative importance of race compared to health care and social factors on prostate cancer specific mortality. MATERIALS AND METHODS: Using the SEER (Surveillance, Epidemiology, and End Results) database we identified 514,878 men diagnosed with prostate cancer at age 40 years or greater between 2004 and 2012. We also selected a subset of black and white men matched by age, stage and birth year. We stratified patients by age 40 to 54, 55 to 69 and 70 years or older and disease stage, resulting in 18 groups. By applying random forest methods with variable importance measures we analyzed 15 variables and interactions across 4 categories of factors (tumor characteristics, race, and health care and social factors) and the relative importance for prostate cancer specific mortality. RESULTS: Tumor characteristics at diagnosis were the most important factors for prostate cancer mortality. Across all groups race was less than 5% as important as tumor characteristics and only more important than health care and social factors in 2 of the 18 groups. Although race had a significant impact, health care and social factors known to be associated with racial disparities had greater or similarly important effects across all ages and stages. CONCLUSIONS: Eradicating disparities in prostate cancer survival will require a multipronged approach, including advances in precision medicine. Disparities will persist unless health care access and social equality are achieved among all populations.
PURPOSE: There is a differential in prostate cancer mortality between black and white men. Advances in precision medicine have shifted the research focus toward underlying genetic differences. However, nonbiological factors may have a large role in these observed disparities. Therefore, we sought to measure the relative importance of race compared to health care and social factors on prostate cancer specific mortality. MATERIALS AND METHODS: Using the SEER (Surveillance, Epidemiology, and End Results) database we identified 514,878 men diagnosed with prostate cancer at age 40 years or greater between 2004 and 2012. We also selected a subset of black and white men matched by age, stage and birth year. We stratified patients by age 40 to 54, 55 to 69 and 70 years or older and disease stage, resulting in 18 groups. By applying random forest methods with variable importance measures we analyzed 15 variables and interactions across 4 categories of factors (tumor characteristics, race, and health care and social factors) and the relative importance for prostate cancer specific mortality. RESULTS:Tumor characteristics at diagnosis were the most important factors for prostate cancer mortality. Across all groups race was less than 5% as important as tumor characteristics and only more important than health care and social factors in 2 of the 18 groups. Although race had a significant impact, health care and social factors known to be associated with racial disparities had greater or similarly important effects across all ages and stages. CONCLUSIONS: Eradicating disparities in prostate cancer survival will require a multipronged approach, including advances in precision medicine. Disparities will persist unless health care access and social equality are achieved among all populations.
Authors: Sarah A Tishkoff; Timothy R Rebbeck; Joseph Lachance; Ali J Berens; Matthew E B Hansen; Andrew K Teng Journal: Cancer Res Date: 2018-02-08 Impact factor: 12.701
Authors: B F Hankey; E J Feuer; L X Clegg; R B Hayes; J M Legler; P C Prorok; L A Ries; R M Merrill; R S Kaplan Journal: J Natl Cancer Inst Date: 1999-06-16 Impact factor: 13.506
Authors: Brandon Bernard; Vinayak Muralidhar; Yu-Hui Chen; Srikala S Sridhar; Edith P Mitchell; Curtis A Pettaway; Michael A Carducci; Paul L Nguyen; Christopher J Sweeney Journal: Cancer Date: 2017-01-05 Impact factor: 6.860
Authors: S Vijayakumar; K Winter; W Sause; M J Gallagher; J Michalski; M Roach; A Porter; M Bondy Journal: Int J Radiat Oncol Biol Phys Date: 1998-01-01 Impact factor: 7.038
Authors: Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544
Authors: Robert T Dess; Holly E Hartman; Brandon A Mahal; Payal D Soni; William C Jackson; Matthew R Cooperberg; Christopher L Amling; William J Aronson; Christopher J Kane; Martha K Terris; Zachary S Zumsteg; Santino Butler; Joseph R Osborne; Todd M Morgan; Rohit Mehra; Simpa S Salami; Amar U Kishan; Chenyang Wang; Edward M Schaeffer; Mack Roach; Thomas M Pisansky; William U Shipley; Stephen J Freedland; Howard M Sandler; Susan Halabi; Felix Y Feng; James J Dignam; Paul L Nguyen; Matthew J Schipper; Daniel E Spratt Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: Mary M Everist; Lauren E Howard; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Martha K Terris; Stephen J Freedland Journal: Urol Oncol Date: 2018-12-28 Impact factor: 2.954
Authors: Nathaniel Oswald; Tengda Lin; Benjamin Haaland; Michael Flynn; Kensaku Kawamoto; Kathleen A Cooney; William Lowrance; Heidi A Hanson; Brock O'Neil Journal: Cancer Epidemiol Date: 2020-05-08 Impact factor: 2.984
Authors: Andrew B Chen; Taseen Haque; Sidney Roberts; Sirisha Rambhatla; Giovanni Cacciamani; Prokar Dasgupta; Andrew J Hung Journal: Urol Clin North Am Date: 2021-10-23 Impact factor: 2.766
Authors: Weichuan Dong; Wyatt P Bensken; Uriel Kim; Johnie Rose; Qinjin Fan; Nicholas K Schiltz; Nathan A Berger; Siran M Koroukian Journal: JAMA Netw Open Date: 2022-09-01
Authors: Abhishek Kumar; Vinit Nalawade; Paul Riviere; Reith R Sarkar; J Kellog Parsons; James D Murphy; Brent S Rose Journal: JAMA Netw Open Date: 2019-10-02